Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event
    Summit & Event ：
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
    Learn More>
    Wealth & Capital Management
    Insurance & Finance
    Healthcare & Pharma
    Retail & FMCG
    Travel & Transportation
  • Shine Speaker Bureau
    Shine Speaker Bureau：
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
    Learn More>
    The Leader Networks
    Advisor
    Think-Tank
  • Shine Advisor
    Shine Advisor：
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
    Learn More>
    Briefing
    Consensus
    Customized Research
  • Shine Event Service
    Shine Event Service：
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
    Learn More>
Guest Information
Jim WU
Jim WU
发布时间: 2019 - 07 - 10
点击次数: 0
Positions： Founer&CEO
Company： Ark Biosciences
个人简介：
Dr. Jim Wu is founder and CEO of Ark Biosciences. Dr. Wu has an extensive and successful pharma experience in which he contributed to development of antiviral, oncology, metabolic and CNS drugs, including Potiga™/Trobalt™ andZurampic™ that were approved by FDA and EMEA for global marketing. He was a senior scientist at Schering-Plough Research Institute, now part of Merck, and director of preclinical and translational research at Valeant Pharmaceuticals. He was a founding scientist of Ribapharm that went for IPO at NYSE in 2002 for $800 million USD. More recently he was a member of China management team and head of biology at Roche R&D Center China, where he held responsibility for oncology, virology and diabetic drug discovery. Dr. Wu was CEO of Sumo Bioscience, a California-based biotech startup before he founded Ark Biosciences in 2013, focusing on antiviral drug discovery and clinical development.Dr. Wu obtained his BSc from University of Science and Technology of China, his PhD from Brown University, and conducted postdoctoral research at Harvard Medical School. He is a coauthor of 60s scientific papers and serves in editorial advisory board of “Antimicrobial Agent and Chemotherapy”. He is also an adjunct professor at Fudan University School of Pharmacy and Shanghai Medical College. In his pharma industrial career, he is a co-inventor of 15 patents and contributed to 6 INDs and 2 NDAs.
查看详情>>
Jinzi WU
Jinzi WU
发布时间: 2019 - 07 - 11
点击次数: 0
Positions： Founder, Chairman & CEO
Company： Ascletis Pharma Inc.
个人简介：
Dr. Jinzi J. Wu is Founder, Chairman and CEO of Ascletis which was founded in April 2013. Ascletis is an innovative R&D driven biotech with two commercial products. Led by Dr. Wu, Ascletis (1672.HK) became the first pre-revenue biotech listed on the Hong Kong Stock Exchange in August 2018 and raised US$400M. Under his leadership, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Led by Dr. Wu, Ganovo® (Danoprevir), Ascletis’ first direct-acting antiviral agent (DAA) for hepatitis C, was successfully launched in June 2018 and is now commercialized by Ascletis’ 180+ member commercial team. Dr. Wu and his team filed NDA in August 2018 for Ravidasvir, Ascletis’ second DAA for hepatitis C with best-in-class characteristics. Under his leadership, Ascletis has built an innovative R&D pipeline focusing on viral, cancer and fatty liver diseases and consisting of antibody-based immunotherapy, first/best-in-class small molecules and siRNA at various clinical development stages. Dr. Wu has more than 20-year experience covering R&D, GMP manufacturing and commercialization in Big Pharma and biotech. Prior to founding Ascletis, he was Vice President at GSK R&D in USA. He also held various R&D positions from Sr. Scientist to Vice President at Novartis, Immunex/Amgen and Ambrilia in USA and Canada. Dr Wu obtained his PhD in Cancer Biology from University of Arizona.
查看详情>>
Mai-Jing LIAO
Mai-Jing LIAO
发布时间: 2019 - 07 - 18
点击次数: 0
Positions： Chief Business Officer
Company： Harbour BioMed
个人简介：
Dr. Mai-Jing Liao brings to HBM more than 12 years of Marketing and Business Development experience. Prior to joining HBM, Dr. Liao was at Xian Janssen Pharmaceutical Ltd. where he served in multiple roles with increasing responsibilities in Marketing, Strategic Marketing and Business Development. He joined J&J's Centocor US subsidiary after receiving his MBA degree from Johnson Graduate School of Management at Cornell University. Dr. Liao received his PhD degree in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill and was a postdoctoral fellow in Dr. Robert Weinberg's laboratory at Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology (MIT).
查看详情>>
Jielun ZHU
Jielun ZHU
发布时间: 2019 - 07 - 18
点击次数: 0
Positions： CFO
Company： I-MAB Biopharma
个人简介：
As the Chief Financial Officer, Jielun Zhu, MBA, CFA, is in charge of the overall financial strategy and management, capital investment, corporate finance and investor relations. He is a veteran and expert in the finance industry, with over 11 years of experience in investment banking. From December 2015 to July 2018, prior to joining I-Mab, he served as a managing director and Asia Head of Healthcare Investment Banking and Capital Markets in Hong Kong for Jefferies Group LLC, a global full-service investment bank with a strong focus in healthcare.At Jefferies, he advised many biotechnology and healthcare clients globally on IPOs and other financings, as well as mergers and acquisitions. From August 2008 to September 2015, he worked for the Deutsche Bank Group in its Hong Kong office. He occupied a succession of positions, with the last one being Director in the Corporate Finance Division, which entailed working with leading clients in the healthcare and other sectors in Greater China. From July 2007 to July 2008, he was an investment banker in Hong Kong with UBS AG. Before investment banking, Mr. Zhu was a strategy consultant in Boston focused on serving clients in the US pharmaceutical and biotechnology industry.Mr. Zhu earned his M.B.A. from the Harvard Business School with distinction in June 2007 and his Bachelor of Arts degree with honors in mathematics-economics from Wesleyan University. He is also a CFA charter holder.
查看详情>>